As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
10 Analysts have issued a Celsion Corporation forecast:
10 Analysts have issued a Celsion Corporation forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -18 -18 |
11%
11%
|
EBIT (Operating Income) EBIT | -18 -18 |
10%
10%
|
Net Profit | -18 -18 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Head office | United States |
CEO | Stacy Lindborg |
Employees | 25 |
Founded | 1982 |
Website | imunon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.